ArriVent BioPharma, Inc. Common Stock
Price Action
Technical Summary
STAGE 2 UPTRENDArriVent BioPharma, Inc. Common Stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings contraction of 13% provides fundamental context to the price action. Investors should exercise caution due to high volatility (56% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $29.59 | +0.10% | ABOVE |
| 50 SMA | $26.02 | +13.82% | ABOVE |
| 100 SMA | $24.06 | +23.11% | ABOVE |
| 150 SMA | $22.84 | +29.68% | ABOVE |
| 200 SMA | $21.92 | +35.14% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVBP in an uptrend right now?
AVBP has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AVBP is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AVBP overbought or oversold?
AVBP's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is AVBP outperforming the market?
AVBP has a Relative Strength (RS) Rating of 88 out of 99. Yes, AVBP is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is AVBP in its 52-week range?
AVBP is trading at $29.62, which is 92% of its 52-week high ($32.14) and 84% above its 52-week low ($16.10).
How volatile is AVBP?
AVBP has a Beta of 1.21 and 52-week volatility of 56%. It's more volatile than the S&P 500 - expect bigger swings.